Literature DB >> 29492083

Recognition of sentinel lymph nodes in patients with papillary thyroid cancer by nano-carbon and methylene blue.

Fangzhou Liu1, Yan Zhu2, Yichuan Qian3, Jia Zhang4, Yu Zhang5, Yuan Zhang6.   

Abstract

OBJECTIVE: To compare the accuracy and feasibility of methylene blue and nano-carbon in clinical tracing of sentinel lymph nodes (SLNs) in patients with papillary thyroid cancer (PTC).
METHODS: Ninety-six PTC patients were selected and randomly divided into a methylene blue group and a nano-carbon group (n=48). During surgery, tracer agent was injected around the tumor, and SLNs were resected and subjected to frozen pathological examination. The results were compared with those of routine pathological examination after surgery.
RESULTS: Latent lymph node metastasis (level VI and lateral neck) was detected in both groups, with neck distribution of SLNs. There was no significant difference in the detection rate or accuracy of SLNs between two groups (P>0.05). The incorrect resection rate of parathyroid gland and incidence of temporary hypoparathyroidism in the methylene blue group were significantly higher than those of the nano-carbon group (t=4.137, P<0.05).
CONCLUSIONS: The state of PTC lymph nodes can be well evaluated by SLN biopsy using both methylene blue and nano-carbon as tracers, but using nano-carbon has a lower incidence rate of parathyroid injury, with great clinical prospects accordingly.

Entities:  

Keywords:  Methylene blue; Nano-carbon; Papillary thyroid cancer; Sentinel lymph node

Year:  2017        PMID: 29492083      PMCID: PMC5768849          DOI: 10.12669/pjms.336.13940

Source DB:  PubMed          Journal:  Pak J Med Sci        ISSN: 1681-715X            Impact factor:   1.088


INTRODUCTION

Papillary thyroid cancer (PTC), despite with the lowest degree of malignancy, accounts for about 85% of thyroid tumors, but its incidence has been increasing annually. It has become the fifth susceptible malignancy for females, which mostly endangers children or young women, with an uncertain age of onset.1,2 Sentinel lymph nodes (SLNs) first drain lymph of primary cancer in local tissues, biopsy for which can accurately predict the state of regional lymph nodes.3 Recently, researchers have endeavored to carry out SLN biopsy for melanoma, breast cancer, penile cancer and colon cancer, providing a scientific basis for determining the surgical range.4 However, SLNs of thyroid cancer have seldom been studied. Nano-carbon, as a novel lymph tracer, has rarely been applied to thyroid cancer therapy. At present, SLN biopsy is mainly traced by staining method, radionuclide method and combination method. For staining method, methylene blue and nano-carbon are mainly employed, which are cheap and expensive respectively. In this study, 96 PTC patients were selected as subjects to compare the detection rate, accuracy and postoperative complications of methylene blue and nano-carbon in the tracing of SLN biopsy.

METHODS

Ninety-six PTC patients admitted in our hospital between April 2016 and February 2017 were selected, and subjected to neck ultrasound, chest X-ray and thyroid function examinations before surgery. There were 19 males and 77 females aged between 45 and 69 years old, with a mean of (51.98 ± 3.1). The patients were randomly divided into a methylene blue group and a nano-carbon group (n=48). The two groups had similar age and gender ratio (P>0.05). This prospective study has been approved by the ethics committee of our hospital, and written informed consent has been obtained from all patients. Sample size (n) of each group = 2(mse/D2) × (Q + μβ), where mse is the mean square of error and D is the inter-group difference. In this study, mse=50u/dl and D=4u/u. Referring to a known table, Q=4.2 and μβ=1.645, so n=2(50/42)×(4.2+1.645)≈37. Therefore, over 37 cases should be included in each group. Considering the actual situation simultaneously, we included 96 cases in total. Sampling was performed using the routine operational steps of frozen pathological analysis.

Inclusion criteria

Patients who were diagnosed as PTC and without cervical lymph node metastasis through preoperative ultrasound examination were included.

Exclusion criteria

Patients with benign thyroid lesions or other types of thyroid cancer diagnosed by intraoperative frozen pathological examination, a history of neck or thyroid surgery or neck radiotherapy, or distant systemic metastasis were excluded.

Determination criteria

According to the clinical evaluation criteria for neck lymph nodes proposed by Kouvaraki et al.,5 the following requirements should all be met: Clinical palpation found no enlarged lymph nodes or the maximum diameter was <20 mm, with soft texture; B ultrasound or CT examination disclosed no enlarged lymph nodes or the maximum diameter was <10 mm, or the maximum diameter was 10-20 mm, with a >2 aspect ratio though. The shape was regular, and the cortex and medulla had clear boundary. There was no sand-like small calcification, central liquefaction necrosis, peripheral enhancement or disappearance of fatty space near lymph nodes; patients who lacked imaging data were diagnosed based on palpation.

Surgical methods

An anterior cervical low-collar incision (2 cm above the suprasternal notch) was made under general anesthesia. The anterior cervical flap and central neck line were separated to expose the thyroid surface and to confirm the location of primary tumor. At the 3-, 6-, 9- and 12-o’clock positions about 1-2 mm around the tumor, 0.2-0.8 mL of 10 g/L methylene blue was injected for the methylene blue group and 1 mL of nano-carbon suspension was injected for the nano-carbon group using a 1 mL syringe. Thyroid gland was kept in the original anatomical position. The lobes of affected thyroid gland were removed 2-5 minutes after oppression on the puncture point with a sterile gauze. There were three cases of lateral cervical lymph node metastasis in two groups each. The surgical approach was bilateral total thyroid lobectomy + level VI lymph node dissection of affected side + levels II-V functional neck dissection of affected side. All remaining cases were given total thyroid lobectomy of affected side + isthmus resection + level VI lymph node dissection of affected side.

Evaluation criteria for SLN biopsy

Using the results of routine postoperative pathological examination as golden standards, the evaluation criteria for SLN biopsy were as follows: 1) Positive: SLN metastasis; 2) negative: no metastasis of SLN or non-SLN. The following indices were calculated: Detection rate = (number of cases with detected SLNs/number of all enrolled cases) × 100%; sensitivity = (number of positive SLN cases/ number of cases with cervical lymph node metastasis) × 100%; accuracy = (number of positive cases + number of negative cases)/number of recognized SLNs × 100%.

Pathological examination and monitoring of postoperative complications

All surgically resected samples (including thyroid gland lobes, SLNs, level VI lymph nodes of affected side, and levels II-V cervical lymph nodes of affected side) were subjected to routine pathological examination. The incorrectly resected parathyroid glands suggested by intraoperative frozen and routine postoperative pathological examinations were counted, and parathyroid hormone and blood calcium levels were detected on the 1st, 3rd and 30th days after surgery, respectively. Whether the patients had tetany, numbness and other symptoms of hypocalcemia was observed. In case of hypocalcemia, calcium was supplemented through intravenous infusion for two days and then through oral administration. Subsequently, the patients were followed up for one year. If there was still hypoparathyroidism and hypocalcemia after drug withdrawal, it was permanent hypoparathyroidism. If not, it was temporary hypoparathyroidism. Whether there were other postoperative complications (incision bleeding, infection, effusion, hoarseness, irritating cough while drinking water, chylous fistula and toxic or allergic reactions caused by injecting tracers) was also observed.

Statistical analysis

All data were analyzed by SPSS 22.0. The categorical data were expressed as x ± s, and inter-group comparisons were performed by the t test. The numerical data were compared by fourfold tables using the Chi-square test or continuity corrected Chi-square test. Areas under the ROC curves were analyzed to compare the accuracy of two methods. The effects of number of detected SLNs on accuracy were assessed by ROC curves. P<0.05 was considered statistically significant.

RESULTS

SLN detection rate and distribution

The SLN detection rate of the methylene blue group (89.6%, 43/48) was similar to that of the nano-carbon group (95.8%, 46/48) (P>0.05) (Table-I). The rate of latent lymph node metastasis was 46.88% (45/96), with 40.63% (39/96) in Level VI and 6.25% (6/96) in lateral neck. In the methylene blue group, 1~4 SLNs were detected in each case, (1.93 ± 0.69) on average. In the nano-carbon group, 1~5 SLNs were detected in each case, (2.60 ± 0.89) on average. There was a significant difference (t=-3.83, P<0.01). The two groups had similar neck distributions of SLNs (P>0.05).
Table-I

SLN detection rate and distribution (case).

GroupTumor sizeTNM stageNumber of SLNsSLN in Level VIPositive SLN in Level VINon-positive SLN in Level VISLN in lateral neckPositive SLN in lateral neckNon-positive SLN in lateral neck

≤1 cm>1 cmT1, T2T3, T4
Methylene blue291932164338173640
Nano-carbon272134144639181730
t1.3621.0231.0351.9101.2661.6541.7811.3541.8741.4562.059
P>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05
SLN detection rate and distribution (case). There was no significant difference in the sensitivity or accuracy of SLNs between the two groups (P>0.05) (Table-II).
Table-II

SLN biopsy-related results (% (case/case)).

GroupSensitivityAccuracy
Methylene blue93.75 (45/48)85.42 (41/48)
Nano-carbon95.83 (46/48)93.75 (45/48)
t1.5791.542
P>0.05>0.05
SLN biopsy-related results (% (case/case)).

Incorrect resection rate of parathyroid gland and temporary hypoparathyroidism

The incorrect resection rate of parathyroid gland in the methylene blue group (16.67%, 8/48) was significantly higher than that of the nano-carbon group (2.08%, 1/48) (t=4.137, P<0.05). Besides, 6 cases (12.50%) in the methylene blue group suffered from temporary hypoparathyroidism, but none in the nano-carbon group did so, between which the difference was significant (t=4.137, P<0.05).

Other complications

Neither group suffered from surgical site bleeding, infection, effusion, postoperative hoarseness, water drinking-induced irritating cough, chylous fistula, or tracer agent injection-induced toxicity or allergic reaction.

DISCUSSION

SLN, as the first stop of tumor metastasis, is the node for drainage of primary cancers in regional lymphoid tissues.6 The metastasis is helpful to determine tumor stage, prognosis and treatment regimen.7 There have been many reports since SLN biopsy was first applied in thyroid cancer surgery in 1998.8-11 Up to now, the SLN tracer methods include radionuclide method, staining method and their combination. In the radionuclide method and the combination method, thyroid SLN is close to tumor, so they can be greatly disrupted by thyroid tumor and thyroid radionuclide, needing special instruments and causing radioactive contamination. Therefore, the application is restricted. Currently, the staining method generally uses methylene blue and nano-carbon suspension, with the SLN detection rates of 66.70%-94.7% and 91.67%-97.20% respectively.12 In this study, the SLN detection rates of methylene blue and nano-carbon groups were 89.6% and 95.8% respectively, without significant differences. Although (2.60 ± 0.89) SLNs were detected in the nano-carbon group, which significantly exceeded that of the methylene blue group (1.93 ± 0.69), the number of each group could not effectively evaluate the accuracy of positive SLNs. Using postoperative routine pathological results as the golden standard, the two groups had similar SLN accuracies. Accordingly, though nano-carbon increased the number of detected SLNs per patient compared with methylene blue, it failed to elevate the detection rate or accuracy (P<0.05). However, the postoperative rate of parathyroid injury (including mistaken incision rate and postoperative temporary hypoparathyroidism) of the nano-carbon group was significantly lower than that of the methylene blue group. Therefore, in the PTC operation of CN0, the nano-carbon method better protected parathyroid glands and reduced the rate of postoperative parathyroid injury compared with the methylene blue method. Probably, when SLN was tracked by nano-carbon, lymph nodes were black, and parathyroid gland was not stained; but when SLN was tracked by methylene blue, both lymph nodes and parathyroid were stained blue, which could hardly be identified.13 PTC is the most common pathological type of thyroid cancer, accounting for 60% to 80% of all thyroid cancers, of which 27% to 90% exist occult lymphatic metastasis.14 Lymph node metastasis is an important factor in PTC recurrence, but its impact on prognosis remains elusive.15 As the lymph node metastasis rate of PTC central region (i.e. Level VI) is high, routine elimination of regional lymph nodes can reduce local regional recurrence rate. In addition, about 20% of PTC may be transferred to lymph nodes outside Level VI at the first stop.16,17 Thus, it is necessary to accurately assess the cervical lymph nodes of CN0 patients, as well as to reduce the complications caused by local recurrence and re-operation due to metastasis. SLN biopsy can identify whether there is regional lymph node metastasis in tumors, which has been widely applied in breast cancer and melanoma.18 Herein, the occult lymph node metastasis rate was 46.88%, of which 40.63% underwent Level VI lymph node metastasis and 6.25% had lateral cervical lymph node metastasis. Therefore, it was necessary to carry out SLN biopsy for PTC patients. Both methylene blue and nano-carbon methods had high accuracies for SLN detection, and had similar SLN distributions in the neck. Hence, both methods can be used in PTC SLN biopsy to evaluate latent lymph node metastasis. Except for parathyroid injury rate, no other complications occurred in either group, suggesting that both methods were safe and reliable for PTC SLN biopsy.

CONCLUSION

In summary, both methylene blue and nano-carbon functioned well in evaluating lymph node states in SLN biopsy, with similar detection rates and accuracies. Nevertheless, compared with the methylene blue method, the nano-carbon method better protected parathyroid gland sand reduced the incidence of postoperative hypoparathyroidism. Thus, the nano-carbon method shows more promising prospects for clinical use.

Authors’ Contributions

Study design and manuscript preparation. Data collection and analysis.
  18 in total

1.  Preoperative needle biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in patients with breast cancer.

Authors:  Ali R Sever; Philippa Mills; Jennifer Weeks; Susan E Jones; David Fish; Peter A Jones; Willem Mali
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

2.  Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8.

Authors:  Weiyuan Fang; Lei Ye; Liyun Shen; Jie Cai; Fengjiao Huang; Qing Wei; Xiaochun Fei; Xi Chen; Haixia Guan; Weiqing Wang; Xiaoying Li; Guang Ning
Journal:  Carcinogenesis       Date:  2014-03-06       Impact factor: 4.944

3.  An approach for the treatment of penile carcinoma.

Authors:  R M Cabanas
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

4.  Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; Young Kee Shong; Tae Yong Kim; David Viola; Rossella Elisei; Bela Bendlová; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Roderick Clifton-Bligh; Giovanni Tallini; Elizabeth H Holt; Vlasta Sýkorová
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

5.  Clinical significance of BRAF mutation in thyroid papillary cancer.

Authors:  Ignacio J Fernandez; Ottavio Piccin; Silvia Sciascia; Ottavio Cavicchi; Andrea Repaci; Valentina Vicennati; Michelangelo Fiorentino
Journal:  Otolaryngol Head Neck Surg       Date:  2013-03-12       Impact factor: 3.497

6.  Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.

Authors:  Xiao-Min Yu; David F Schneider; Glen Leverson; Herbert Chen; Rebecca S Sippel
Journal:  Thyroid       Date:  2013-09-11       Impact factor: 6.568

7.  Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis.

Authors:  Yu Lun; Xiaoyu Wu; Qian Xia; Yanshuo Han; Xiaoyu Zhang; Zhimin Liu; Fengyi Wang; Zhiquan Duan; Shijie Xin; Jian Zhang
Journal:  Otolaryngol Head Neck Surg       Date:  2013-01-08       Impact factor: 3.497

8.  Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: a prospective study.

Authors:  Pedro W Rosário; Wilson C Tavares; Michelle A R Borges; Juan Bernard N Santos; Maria Regina Calsolari
Journal:  Endocr Pract       Date:  2014-04       Impact factor: 3.443

9.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07

10.  Application of nano-carbon in lymph node dissection for thyroid cancer and protection of parathyroid glands.

Authors:  Wuguo Tian; Yan Jiang; Bo Gao; Xiaohua Zhang; Shu Zhang; Jianjie Zhao; Yujun He; Donglin Luo
Journal:  Med Sci Monit       Date:  2014-10-14
View more
  6 in total

1.  Mitoxantrone hydrochloride injection for tracing helps to decrease parathyroid gland resection and increase lymph node yield in thyroid cancer surgery: a randomized clinical trial.

Authors:  Shaobo Chen; Xianming Hou; Surong Hua; Ziwen Liu; Binglu Li; Xiaoyi Li; Lin Cong; Quan Liao; Jugao Fang; Lizhen Hou; Shanghua Jing; Zhen Zhao; Jianwu Qin; Songtao Zhang; Zhendong Li; Dongning Huang; Ning Zhang; Yongfu Zhao; Jun Liu; Shujun Wang; Ge Chen; Yupei Zhao
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Infiltration of nanocarbon suspension into the tracheal cavity during surgical treatment of papillary thyroid carcinoma: a case report.

Authors:  Lin-Bo Zhu; Feng Zhu; Peng-Fei Li; Peng-Bin Zhang
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

3.  Role of carbon nanotracers in lymph node dissection of advanced gastric cancer and the selection of preoperative labeling time.

Authors:  Kai Zhao; Bao-Qiang Shan; Yan-Peng Gao; Jia-You Xu
Journal:  World J Clin Cases       Date:  2022-01-21       Impact factor: 1.337

4.  Comparison of two suspension injection tracers of nano activated carbon and methylene blue in mapping and tracing of sentinel lymph nodes of patients with endometrial cancer.

Authors:  Weifeng Zhang; Yan Shu; Dongmei Ni; Zeqiu Wan; Shuying Yang
Journal:  Pak J Med Sci       Date:  2022 Jul-Aug       Impact factor: 2.340

5.  Detection Rate and Prognosis of Lymph Nodes in Gastric Cancer Using Nano Carbon Combined with In Vitro Anatomical Sorting.

Authors:  Jun Ma; Chongren Ren; Gang Du; Jinxi Wang; Zhenguo Han; Huhu Li; Huiyu Li; Liang Xue
Journal:  Comput Intell Neurosci       Date:  2022-08-23

6.  The role of carbon nanoparticle in lymph node detection and parathyroid gland protection during thyroidectomy for non-anaplastic thyroid carcinoma- a meta-analysis.

Authors:  Shaowei Xu; Zhifeng Li; Manbin Xu; Hanwei Peng
Journal:  PLoS One       Date:  2020-11-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.